echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nature Cancer: Lui Zhimin/Hatchie team reveals new mechanism to overcome immune checkpoint inhibitor resistance

    Nature Cancer: Lui Zhimin/Hatchie team reveals new mechanism to overcome immune checkpoint inhibitor resistance

    • Last Update: 2022-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Patients with EGFR mutation-activated non-small cell lung cancer (NSCLC) are not sensitive to immune checkpoint inhibitor therapy, which is the bottleneck
    of lung cancer immunotherapy.
    The continuous discovery and elucidating of new mechanisms of tumor immune evasion regulated by tumor microenvironment have brought new hope
    to these NSCLC patients.

    Recently, the team of Lu Zhimin, Institute of Translational Medicine of Zhejiang University/The First Affiliated Hospital of Zhejiang University School of Medicine, together with the team of Academician Hejie of the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, published a cover article in the journal Nature Cancer entitled : Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade,

    The study revealed that the combination of CD55/CD59 antibodies and PD-1 antibodies can overcome the non-response
    to immune checkpoint inhibitor therapy in NSCLC patients with EGFR mutations.

    The complement system recognizes foreign pathogens and autocells expressing abnormal surface molecules to trigger the release of inflammatory mediators, recruitment of immune cells, phagocytosis, and cell lysis
    .
    At the same time, the complement system is tightly negatively regulated and inhibited
    by membrane-bound complement regulatory proteins (mCRPs, including CD55 and CD59).

    Lui and Hatchie's team found that EGFR mutation activation in NSCLC cells increased the expression of CD55 and CD59 in tumor cells, inhibited complement activation and CD8+ T cell activity
    .
    Further studies found that EGFR mutation activation caused β-catenin to bind to the promoter of the long non-coding RNA LINC00973, thereby inducing LINC00973 expression
    .

    LINC00973 upregulates the expression of CD55 and CD59 by adsorbing miR-216b and miRNA-150, thereby inhibiting the function of immune cells in the tumor microenvironment mediated by complement activation, and finally achieving tumor immune escape
    .
    Studies have shown that the combination of CD55/CD59 antibody and PD-1 antibody is more effective in promoting the infiltration of CD8+ T cells and M1 macrophages in tumors, thereby inhibiting tumor growth and significantly prolonging the survival time
    of tumor-bearing mice.

    EGFR/β-catenin-mediated mechanisms of complement inhibition, immune cell function inhibition, and subsequent promotion of tumor growth

    This study revealed the intrinsic regulatory relationship between complement and immune cells in the tumor microenvironment, and provided preclinical evidence that the new strategy of combined blocking mCRP function and PD-1/PD-L1 checkpoint treatment of EGFR mutation activation NSCLC has high clinical translational value
    .

    This study is another important achievement
    of Lui Zhimin's team in the research direction of tumor metabolic immunity, following the mechanism of tumor cell AKT/β-catenin pathway regulation of immune checkpoint PD-L1 (Journal of Experimental Medicine, August 2020) and the disclosure of tumor cell Warburg effect to promote tumor immune evasion (Cell Metabolism, August 2022).

    Original source:

    Shao, F.
    , Gao, Y.
    , Wang, W.
    et al.
    Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.
    Nat Cancer 3, 1192–1210 (2022).
    https://doi.
    org/10.
    1038/s43018-022-00444-4.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.